Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice

Tubercle and Lung Disease

Volumn 78, Issue 5-6, 1997, Pages 237-246

  Adams, L B ^a   Dinauer, M C ^b   Morgenstern, D E ^b   Krahenbuhl, J L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; CYTOCHROME C OXIDASE; GAMMA INTERFERON; NITRIC OXIDE SYNTHASE; NITRITE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; KNOCKOUT MOUSE; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTE DYSFUNCTION; PRIORITY JOURNAL; SPLEEN; STRAIN DIFFERENCE; SURVIVAL TIME; TRANSGENIC MOUSE; TUBERCULOSIS;

EID: 0031396678     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(97)90004-6     Document Type: Article

References (65)

1. Nathan C F, Murray H W, Weibe M E, Rubin B Y. Identification of interferon gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670.
2. Adams D O, Hamilton T A. The activated macrophage and granulomatous inflammation. Curr Top Pathol 1989; 79: 151-167.
3. Rook G A W. Role of activated macrophages in the immunopathology of tuberculosis. Br Med Bull 1988; 44: 611-625.
4. Ding A H, Nathan C F, Stuehr D J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141: 2407-2412.
5. Robinson J M, Badwey J A. Production of active oxygen species by phagocytic leukocytes. In: Zwilling B S, Eisenstein T K, eds. Macrophage-Pathogen Interactions. New York: Marcel Dekker, Inc. 1994: pp 159-178.
6. Bastian N R, Hibbs J B J. Assembly and regulation of NADPH oxidase and nitric oxide synthase. Curr Opin Immunol 1994; 6: 131-139.
7. Dinauer M. The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci 1993; 30: 329-369.
8. Roos D. The genetic basis of chronic granulomatous disease. Immunol Rev 1994; 138: 121-157.
9. Hibbs J J B, Vavrin Z, Taintor R R. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-565.
10. Hibbs J J B, Granger D L, Krahenbuhl J L, Adams L B. Synthesis of nitric oxide from L-arginine: a cytokine inducible pathway with antimicrobial activity. In: van Furth R ed. Mononuclear Phagocytes: Biology of Monocytes and Macrophages. Dordrecht: Kluwer 1992: pp 279-292.
11. Stamler J S, Singel D J, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-1902.
12. Pollock J D, Williams D A, Gifford M A C et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9: 202-209.
13. Morgenstern D E, Gifford M A C, Li L L, Doerschuk C M, Dinauer M C. Absence of respiratory burst in X-linked chronic granulomaotus disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 1997; 185: 207-218.
14. Laubach V E, Shesely E G, Smithies O, Sherman P A. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995; 92: 10688-10692.
15. MacMicking J D, Nathan C, Horn G et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81: 641-650.
16. MacMicking J D, North RJ, LaCourse R, Mudgett J S, Shah S K, Nathan C F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 5243-5248.
17. Krahenbuhl J L, Adams L B. The role of the macrophage in resistance to the leprosy bacillus. In: Zwilling B S, Eisenstein T K eds. Macrophage-Pathogen Interactions. New York: Marcel Dekker Inc. 1994: pp 281-302.
18. Adams L B, Krahenbuhl J L. Granulomas induced by Mycobacterium leprae. Methods 1996; 9: 220-232.
19. Grover A A, Kim H K, Wiegeshaus E H, Smith D W. Hostparasite relationships in experimental airborne tuberculosis. II. Reproducible infection by means of an inoculum preserved at -70°C. J Bacteriol 1967; 94: 832-840.
20. Sibley L D, Krahenbuhl J L Induction of unresponsiveness to gamma interferon in macrophages infected with Mycobacterium leprae. Infect Immun 1988; 56: 1912-1919.
21. Senior R M, Campbell E J, Villiger B. Obtaining and culturing human and animal alveolar macrophages. In: Adams D O, Edelson P J, Koren H S eds. Methods for Studying Mononuclear Phagocytes. New York: Academic Press 1981: pp 69-83.
22. Griffiths M J D, Messent M, MacAllister R J, Evans T W. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993; 110: 963-968.
23. Misko T P, Moore W M, Kasten T P et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119-125.
24. Adams L B, Mason C M, Kolls J K, Scollard D, Krahenbuhl J L, Nelson S. Exacerbation of acute and chronic murine tuberculosis by administration of a TNF receptor-expressing adenovirus. J Infect Dis 1995; 171: 400-405.
25. Adams L B, Franzblau S G, Vavrin Z, Hibbs J B Jr, Krahenbuhl J L. L-arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J Immunol 1991; 147: 1642-1646.
26. North R J. Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol 1973; 7: 166-176.
27. Orme I M, Miller E S, Roberts A D et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992; 148: 189-196.
28. Flynn J L, Goldstein M M, Triebold KJ, Koller B, Bloom B R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12013-12017.
29. Ladel C H, Blum C, Dreher A, Reifenberg K, Kaufmann SHE. Protective role of g/d T cells and a/B T cells in tuberculosis. Eur J Immunol 1995; 25: 2877-2881.
30. D'Souza C, Cooper A M, Frank A A, Mazzaccaro R J, Bloom B R, Orme I M. An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J Immunol 1997; 158: 1217-1221.
31. Cooper A M, D'Souza C, Frank A A, Orme I M. The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perfbrin- or granzyme-mediated cytolytic mechanisms. Infect Immun 1997; 65: 1317-1320.
32. Laochumroonvorapong P, Wang J, Liu C-C et al. Perform, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect Immun 1997; 65: 127-132.
33. Dalton D, Pitts-Meek S, Keshav S, Figari I S, Bradley A, Stewart T A. Multiple defects of immune cell function in mice with disrupted interferon-g genes. Science 1993; 259: 1739-1742.
34. Cooper A M, Dalton D K, Stewart T A, Griffin J P, Russell D G, Orme I M. Disseminated tuberculosis in interferon-g gene disrupted mice. J Exp Med 1993; 178: 2243-2247.
35. Flynn J L, Chan J, Triebold KJ, Dalton D K, Stewart T A, Bloom B R. An essential role for interferon-g in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
36. Kamijo R, Le J, Shapiro D et al. Mice that lack the interferon-g receptor have profoundly altered responses to infection with bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435-1440.
37. Vordermeier H M, Venkataprasad N, Harris D P, Ivanyi J. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin Exp Immunol 1996; 106: 312-316.
38. Shiloh M U, Ruan J, Nathan C. Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay. Infect Immun 1997; 65: 3193-3198.
39. Swartz R P, Naai D, Vogel C-W, Yeager H Jr. Differences in uptake of mycobacteria by human monocytes: a role for complement. Infect Immun 1988; 56: 2223-2227.
40. Schlesinger L S, Bellinger-Kawahara C G, Payne N R, Horwitz M A. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol 1990; 144: 2771-2780.
41. Stokes R W, Haidl I D, Jefferies W A, Speert D P. Mycobacteria-macrophage interactions. Macrophage phenotype determines the nonopsonic binding of Mycobacterium tuberculosis to murine macrophages. J Immunol 1993; 151: 7067-7076.
42. Miller R A, Britigan B E. Role of oxidants in microbial pathophysiology. Clin Microbiol Rev 1997; 10: 1-18.
43. Crowle A J, Dahl R, Ross E, May M H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun 1991; 59: 1823-1831.
44. Sturgill-Koszycki S, Schlesinger P H, Chakraborty P et al. Lack of acidification of Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 263: 678-681
45. Brozna J P, Horan M, Rademacher J M, Pabst K M, Pabst M J. Monocyte responses to sulfatide from Mycobacterium tuberculosis: inhibition of priming for enhanced release of superoxide, associated with increased secretion of interleukin-1 and tumor necrosis factor alpha, and altered protein phosphorylation. Infect Immun 1991; 59: 2542-2548.
46. Wadee A A, Clara A M. A 25-kilodalton fraction from Mycobacterium tuberculosis that inhibits hexose monophosphate shunt activity, lysozyme release, and H202 production: reversal by gamma interferon. Infect Immun 1989; 57: 864-869.
47. Chan J, Fan X, Hunter S W, Brennan P J, Bloom B R. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59: 1755-1761.
48. Sibley L D, Hunter S W, Brennan P J, Krahenbuhl J L. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun 1988; 56: 1232-1236.
49. Sibley L D, Adams L B, Krahenbuhl J L. Inhibition of interferon-gamma-mediated activation in mouse macrophages treated with lipoarabinomannan. Clin Exp Immunol 1990; 80: 141-148.
50. Jackett P S, Aber V R, Lowrie D B. Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. Journal of General Microbiology 1978; 104: 37-45.
51. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli. American Review of Tuberculosis 1954; 69: 471-472.
52. Flesch IE, Kaufmann SHE. Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun 1991; 59: 3213-3218.
53. Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991; 132: 150-157.
54. Chan J, Xing Y, Magliozzo R S, Bloom B R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175: 1111-1122.
55. Rhoades E R, Orme I M. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun 1997; 65: 1189-1195.
56. North R J. Mycobacterium tuberculosis is strikingly more virulent for mice when given via the respiratory than via the intravenous route. J Infect Dis 1995; 172: 1550-1553.
57. Orme I M, Collins F M. Mouse model of tuberculosis. In: Bloom B R ed. Tuberculosis: Pathogenesis, Protection and Control. Washington DC: American Society for Microbiology 1994: pp 113-134.
58. Orme I M. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987; 138: 293-298.
59. Douvas G S, Looker D L, Vatter A E, Crowle A J. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 1985; 50: 1-8.
60. Lau Y L, Chan G C F, Ha S Y, Hui Y F, Yuen K Y. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis 1998; 26: 226-227.
61. Sponseller P D, Malech H L, McCarthy J E F, Horowitz S F, Jaffe G, Gallin J I. Skeletal involvement in children who have chronic granulomatous disease. J Bone Joint Surg Am 1991; 73-A: 37-51.
62. Moskaluk C A, Pogrebniak H W, Pass H I, Gallin J I, Travis W D. Surgical pathology of the lung in chronic granulomatous disease. Am J Clin Pathol 1994; 102: 684-691.
63. Hibbs J B Jr, Westenfelder C, Taintor R et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992; 89: 867-877.
64. Nicholson S, Bonecini-Almeida M G, Lapa e Silva J R et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996; 183: 2293-2302.
65. Rich E A, Torres M, Sada E, Finegan C K, Hamilton B D, Toossi Z. Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuberc and Lung Dis 1997; 5&6: 247-255.